Literature DB >> 12893433

Human herpes viruses in non-melanoma skin cancers.

A Zafiropoulos1, E Tsentelierou, K Billiri, D A Spandidos.   

Abstract

We examined the possible involvement of human herpes viruses in sporadic non-melanoma skin cancer of Greek patients. Polymerase chain reaction (PCR) based detection assays were utilized for the detection of viral cytomegalovirus (CMV), herpes simplex virus (HSV) and Epstein-Barr virus (EBV) genomes in 24 squamous cell carcinomas (SCC), five Bowen's disease, 72 basal cell carcinomas (BCC) specimens and eight premalignant lesions. Forty-two of 109 (38.5%) skin lesions were found positive for CMV DNA. The highest incidence was 6/8 (75%) observed in specimens with premalignant lesions. The incidence was 37.5% (27/72) in BCC, 33% (8/24) in SCC and 20% (1/5) in extragenital Bowen's disease. All samples were negative for HSV-1/2 and EBV DNA as assessed by our PCR based assay. The CMV infection showed no statistically significant correlation with the histological type, age, site of lesion or sex. Our results give a strong indication of the possible involvement of CMV in non-melanoma skin cancer development.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12893433     DOI: 10.1016/s0304-3835(03)00269-6

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  15 in total

1.  Profiling of microRNAs modulating cytomegalovirus infection in astrocytoma patients.

Authors:  Ravindra Pramod Deshpande; Manas Panigrahi; Chandrasekhar Y B V K; Phanithi Prakash Babu
Journal:  Neurol Sci       Date:  2018-08-08       Impact factor: 3.307

2.  STING Sensing of Murine Cytomegalovirus Alters the Tumor Microenvironment to Promote Antitumor Immunity.

Authors:  Nicole A Wilski; Colby Stotesbury; Christina Del Casale; Brian Montoya; Eric Wong; Luis J Sigal; Christopher M Snyder
Journal:  J Immunol       Date:  2020-04-13       Impact factor: 5.422

3.  Murine Cytomegalovirus Infection of Melanoma Lesions Delays Tumor Growth by Recruiting and Repolarizing Monocytic Phagocytes in the Tumor.

Authors:  Nicole A Wilski; Christina Del Casale; Timothy J Purwin; Andrew E Aplin; Christopher M Snyder
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

4.  Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma.

Authors:  Duane A Mitchell; Weihua Xie; Robert Schmittling; Chris Learn; Allan Friedman; Roger E McLendon; John H Sampson
Journal:  Neuro Oncol       Date:  2007-10-19       Impact factor: 12.300

Review 5.  Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines.

Authors:  Lee A Selznick; Mohammed F Shamji; Peter Fecci; Matthias Gromeier; Allan H Friedman; John Sampson
Journal:  Neurosurg Rev       Date:  2008-02-08       Impact factor: 3.042

6.  HCMV activates the IL-6-JAK-STAT3 axis in HepG2 cells and primary human hepatocytes.

Authors:  Quentin Lepiller; Wasim Abbas; Amit Kumar; Manoj K Tripathy; Georges Herbein
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

7.  Detection of human cytomegalovirus in normal and neoplastic breast epithelium.

Authors:  Lualhati E Harkins; Lisa A Matlaf; Liliana Soroceanu; Katrin Klemm; William J Britt; Wenquan Wang; Kirby I Bland; Charles S Cobbs
Journal:  Herpesviridae       Date:  2010-12-23

8.  Cytomegalovirus and tumors: two players for one goal-immune escape.

Authors:  Quentin Lepiller; Kashif Aziz Khan; Vincent Di Martino; Georges Herbein
Journal:  Open Virol J       Date:  2011-06-01

9.  Increased HCMV seroprevalence in patients with hepatocellular carcinoma.

Authors:  Quentin Lepiller; Manoj K Tripathy; Vincent Di Martino; Bernadette Kantelip; Georges Herbein
Journal:  Virol J       Date:  2011-10-27       Impact factor: 4.099

10.  CD8+ Immunosenescence Predicts Post-Transplant Cutaneous Squamous Cell Carcinoma in High-Risk Patients.

Authors:  Matthew J Bottomley; Paul N Harden; Kathryn J Wood
Journal:  J Am Soc Nephrol       Date:  2015-11-12       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.